VERAXA Biotech and ATUM Collaborate on BiTAC-TCE Cell Line Development

VERAXA Biotech (NASDAQ: VRXA) has announced a collaboration with ATUM to initiate cell line development for its lead BiTAC(R) T-cell engager program. The partnership will leverage ATUM's Leap-In Transposase(R) technology to generate stable clonal cell lines, supporting IND/CTA-enabling activities and future clinical development. This move follows encouraging preclinical data presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The collaboration aims to bolster CMC development, including early process, analytical, and formulation development, as well as produce material for nonclinical studies.

VERAXA's BiTAC-TCE platform is designed to enhance tumor selectivity by splitting the T-cell engager into two complementary precursors that activate only when both bind separate tumor targets on the same cell. This conditional “AND”-gated approach is intended to reduce off-tumor toxicity typically associated with conventional T-cell engagers while preserving anti-cancer activity. By potentially enabling higher dosing and a broader therapeutic window, VERAXA hopes to improve treatment outcomes for patients with solid tumors. The company believes this innovative design could overcome key limitations of existing immunotherapies.

VERAXA, headquartered in Los Angeles, CA, is building a premier engine for next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other formats. The company was founded on scientific breakthroughs at the European Molecular Biology Laboratory (EMBL). For more details, view the full press release at https://ibn.fm/FCIlk. As with any forward-looking statements, investors should consider the risks outlined in VERAXA's filings with the SEC.